This week we say farewell to Austria and head North-West, across the United Kingdom and land in the Emerald Isle, Ireland, where we arrive at our destination, Dublin. The capital city of Ireland is the home of the very famous Irish dry stout, Trinity College (plus its stunning library) and a nearly 900-year-old cathedral. It is also the residence for our biotech of the week: Opsona Therapeutics
City: Dublin, Ireland
Financial Data: €51.7M total raised (as of 02/15)
Employees: 19 (02/15)
Mission: Opsona Therapeutics is currently at the forefront of drug development in immunology research, with the focus being on the modulation of the human innate immune system. Opsona is primarily looking into tackling the pathways that initiate the innate immune system, such as Toll-Like Receptors (TLRs) and the inflammasome. They currently have one product in the pipeline, OPN-305, a TLR-specific monoclonal antibody and pre-clinical data indicates it is a potent inhibitor of TLR mediated pro-inflammatory cytokine production.